The Administrative Court of Versailles decided on 21 June 1994 that a loan granted by a bank to the executive chairman of a company and then consequently made available to that company is not subject to the provisions of Article 39-1-3° of the French General Tax Code (relating to limits of interest paid to a shareholder) in the following circumstances : the loan had been granted to the chairman, in his capacity as executive chairman, considering the personal guaranties offered, and had been paid directly to the company which then repaid it and met all interest payments, without remunerating the executive chairman.
The same Court also decided on 5 July 1994 that Article 39-1-3° of the French General Tax Code, which limits the deduction of interest paid by a company to its shareholders should be interpreted strictly. Notably, the exchange loss relating to a foreign currency loan should not be taken into consideration in order to calculate if the limit is reached.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances. For additional information contact Claire Acard on +33 (1) 55 61 10 10. The members of ARCHIBALD ANDERSEN Association d'Avocats (S.G. Archibald and Arthur Andersen International) are registered with the Hauts-de-Seine Bar.
Copyright Mondaq Ltd 1995 Tel +44 171 820 7733.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
In this section, we give a factual overview of a significant case development at EU level, and then provide a more detailed analysis of the important substantive and procedural developments addressed in this case.
Sayenko Kharenko's antitrust team has provided legal assistance in obtaining merger clearance with the Antimonopoly Committee of Ukraine (the "AMC") for the EUR 22.8 billion acquisition of Sanofi's animal health (AH) business ("Merial") by Boehringer Ingelheim through an asset swap in exchange for Boehringer Ingelheim's consumer healthcare (CHC) business.
Some comments from our readers… “The articles are extremely timely and highly applicable” “I often find critical information not available elsewhere” “As in-house counsel, Mondaq’s service is of great value”
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).